Clinical Trial: A Phase III Clinical Trial on the Efficacy and Safety of Deuremidevir Hydrobromide Dry Suspension for the Treatment of RSV Infection in Infants and Young Children

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07402512) titled 'A Phase III Clinical Trial on the Efficacy and Safety of Deuremidevir Hydrobromide Dry Suspension for the Treatment of RSV Infection in Infants and Young Children' on Feb. 04.

Brief Summary: This is a randomized, double-blind, placebo-controlled, parallel-group trial conducted in infants and young children aged 1 to 36 months with RSV infection.

A total of 498 subjects are expected to be enrolled and randomly assigned to the investigational product group or the placebo group in a 2:1 ratio; Administration will be based on the subject's weight, with a dose of 20 mg/kg three times daily for 5 consecutive days (15 doses).

Study Start...